Mind Medicine (MindMed) Future Growth
Future criteria checks 0/6
Mind Medicine (MindMed) is forecast to grow earnings and revenue by 36.3% and 86.8% per annum respectively. EPS is expected to grow by 37.4% per annum. Return on equity is forecast to be -50.6% in 3 years.
Key information
36.3%
Earnings growth rate
37.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 86.8% |
| Future return on equity | -50.6% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -129 | -126 | -114 | 8 |
| 12/31/2025 | N/A | -115 | -93 | -83 | 9 |
| 12/31/2024 | N/A | -102 | -74 | -73 | 9 |
| 9/30/2024 | N/A | -98 | -74 | -74 | N/A |
| 6/30/2024 | N/A | -102 | -74 | -74 | N/A |
| 3/31/2024 | N/A | -125 | -68 | -68 | N/A |
| 12/31/2023 | N/A | -96 | -64 | -64 | N/A |
| 9/30/2023 | N/A | -77 | -57 | -57 | N/A |
| 6/30/2023 | N/A | -75 | -49 | -49 | N/A |
| 3/31/2023 | N/A | -63 | -51 | -51 | N/A |
| 12/31/2022 | N/A | -57 | -50 | -50 | N/A |
| 9/30/2022 | N/A | -69 | -45 | -45 | N/A |
| 6/30/2022 | N/A | -69 | -53 | -53 | N/A |
| 3/31/2022 | N/A | -98 | -49 | -49 | N/A |
| 12/31/2021 | N/A | -93 | -46 | -46 | N/A |
| 9/30/2021 | N/A | -89 | -45 | -45 | N/A |
| 6/30/2021 | N/A | -80 | -34 | -34 | N/A |
| 3/31/2021 | N/A | -41 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -34 | -24 | -24 | N/A |
| 9/30/2020 | N/A | -29 | -22 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MMQ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MMQ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MMQ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MMQ is forecast to have no revenue next year.
High Growth Revenue: MMQ is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MMQ is forecast to be unprofitable in 3 years.